(Q53175859)

English

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

scientific article published on 2 April 2012

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

title

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

main subject

ruxolitinib

1 reference

stated in

ChEBI release 2020-05-28

ChEBI ID

66919

ruxolitinib phosphate

1 reference

stated in

ChEBI release 2020-05-28

John Mascarenhas

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

Ronald Hoffman

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

language of work or name

English

0 references

publication date

2 April 2012

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

published in

Clinical Cancer Research

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

volume

18

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

issue

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

page(s)

3008-3014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

Identifiers

DOI

10.1158/1078-0432.CCR-11-3145

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

PubMed publication ID

22474318

1 reference

stated in

Europe PubMed Central

PubMed publication ID

22474318

retrieved

12 May 2018

reference URL

http://europepmc.org/abstract/MED/22474318

(Q53175859)

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)